Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Replimune (REPL) shares plunged ~28% in the premarket on Tuesday after the FDA released a briefing document ahead of an advisory committee meeting scheduled to discuss the marketing application for ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming October 5, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who ...

The last time I spoke about Replimune Group, Inc. (REPL), it was with a Seeking Alpha article entitled "Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating." With respect to this ...

A string trimmer is an invaluable piece of your lawn care tool box. Whether you’re tidying up the edges along sidewalks, freshening in and around flowerbeds, or adding a crisp edge to your driveway, ...

FDA advisory panel votes 10-3 that RP1 trial data show patient benefit Replimune seeks accelerated approval for RP1 with Opdivo in refractory or advanced melanoma FDA decision on RP1 is expected by ...

Residents of the Great Lakes State can expect mild summers, cold, snowy winters and a relatively low cost of living. Here are the 28 Michigan cities ranked in this year's Best Places to Live, from ...

REPL stock surged about 107% at close after an independent panel of experts advised the U.S. Food and Drug Administration in favor of its experimental treatment for advanced melanoma last week. SNOW ...

・Iovance Biotherapeutics reported strong Q2 results, with revenue reaching $99.3 million on rising Amtagvi demand. ・FDA granted Replimune accelerated approval for TUDRIQEV (RP1) combined with ...